Bio Usawa is a biotechnology company that develops monoclonal antibodies for cancer, ophthalmic, and infectious diseases.
Bio Usawa has raised $500K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2025.
Bio Usawa is headquartered in San Francisco, United States.
Bio Usawa is a biotechnology company that develops monoclonal antibodies for cancer, ophthalmic, and infectious diseases.
Bio Usawa is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bio Usawa — Funding & Investors." VCBacked, December 17, 2025, https://www.vcbacked.co/company/bio-usawa. Accessed September 30, 2026.
VCBacked. (2025). Bio Usawa — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/bio-usawa
{{cite web |title=Bio Usawa — Funding & Investors |url=https://www.vcbacked.co/company/bio-usawa |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated